[go: up one dir, main page]

MA25563A1 - Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese. - Google Patents

Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese.

Info

Publication number
MA25563A1
MA25563A1 MA26619A MA26619A MA25563A1 MA 25563 A1 MA25563 A1 MA 25563A1 MA 26619 A MA26619 A MA 26619A MA 26619 A MA26619 A MA 26619A MA 25563 A1 MA25563 A1 MA 25563A1
Authority
MA
Morocco
Prior art keywords
angiogenically
pyridines
inhibiting activity
substituted pyridazines
pyridazines
Prior art date
Application number
MA26619A
Other languages
English (en)
Inventor
Lee Wendy
Nagarathnam Dhanapalan
Su Ning
P Dumas Jacques
A Dixon Julie
Kite Joe Teddy
C E Kluender Harold
N Sibley Robert
J Boyer Stephen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA25563A1 publication Critical patent/MA25563A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MA26619A 1999-09-28 2002-04-26 Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese. MA25563A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
MA25563A1 true MA25563A1 (fr) 2002-10-01

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26619A MA25563A1 (fr) 1999-09-28 2002-04-26 Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese.

Country Status (35)

Country Link
EP (1) EP1228063B1 (fr)
JP (1) JP4919567B2 (fr)
KR (3) KR100895572B1 (fr)
CN (3) CN100422173C (fr)
AR (3) AR025752A1 (fr)
AT (1) ATE422494T1 (fr)
AU (1) AU782820B2 (fr)
BG (1) BG65860B1 (fr)
BR (1) BRPI0014382B8 (fr)
CA (1) CA2385817C (fr)
CO (1) CO5200835A1 (fr)
CZ (1) CZ304767B6 (fr)
DE (1) DE60041548D1 (fr)
DO (1) DOP2000000070A (fr)
EE (1) EE05258B1 (fr)
ES (1) ES2320525T3 (fr)
GT (1) GT200000158A (fr)
HR (1) HRP20020308A2 (fr)
HU (1) HU230223B1 (fr)
IL (3) IL148880A0 (fr)
MA (1) MA25563A1 (fr)
MX (1) MXPA02003156A (fr)
MY (3) MY143580A (fr)
NO (1) NO20021520L (fr)
NZ (1) NZ518589A (fr)
PA (1) PA8503201A1 (fr)
PE (1) PE20010607A1 (fr)
PL (1) PL205957B1 (fr)
RS (1) RS50369B (fr)
RU (1) RU2260008C2 (fr)
SK (1) SK287417B6 (fr)
TW (1) TW593315B (fr)
UA (1) UA75053C2 (fr)
WO (1) WO2001023375A2 (fr)
ZA (1) ZA200202760B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154034A0 (en) * 2000-08-09 2003-07-31 Astrazeneca Ab Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
JP2006519807A (ja) * 2003-03-11 2006-08-31 ノバルティス アクチエンゲゼルシャフト 癌およびｍａｐキナーゼ関連疾患の処置のためのイソキノリン誘導体の使用
US20070082910A1 (en) * 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
EP2364699A1 (fr) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Utilisation conjointe d'un composé à base de sulfonamide avec un inhibiteur de l'angiogénèse
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
CA2648957A1 (fr) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Composes pour traiter une hypertension pulmonaire
CA2652442C (fr) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Agent antitumoral destine au cancer de la thyroide
EP2065372B1 (fr) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
CN107129502B (zh) 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
US12421228B2 (en) * 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
HU219864B (hu) * 1994-08-09 2001-08-28 Eisai Co., Ltd. cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
DE60028740T2 (de) * 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
ES2241781T3 (es) * 2000-02-09 2005-11-01 Novartis Ag Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf.

Also Published As

Publication number Publication date
CZ304767B6 (cs) 2014-10-08
CN1769283A (zh) 2006-05-10
KR20020038775A (ko) 2002-05-23
AR025752A1 (es) 2002-12-11
NZ518589A (en) 2005-03-24
ZA200202760B (en) 2003-10-29
RU2260008C2 (ru) 2005-09-10
KR100895571B1 (ko) 2009-04-29
CN100374435C (zh) 2008-03-12
PE20010607A1 (es) 2001-07-12
BR0014382A (pt) 2003-06-24
HUP0202704A3 (en) 2003-12-29
JP4919567B2 (ja) 2012-04-18
EE200200161A (et) 2003-08-15
HRP20020308A2 (en) 2004-06-30
MY135058A (en) 2008-01-31
SK5912002A3 (en) 2003-01-09
IL193367A (en) 2011-03-31
NO20021520L (no) 2002-05-23
NO20021520D0 (no) 2002-03-26
IL193368A0 (en) 2009-02-11
IL193368A (en) 2011-05-31
KR100890473B1 (ko) 2009-03-26
MY143580A (en) 2011-05-31
PA8503201A1 (es) 2002-08-26
KR100895572B1 (ko) 2009-04-29
BG106637A (bg) 2003-02-28
DOP2000000070A (es) 2002-02-28
UA75053C2 (en) 2006-03-15
SK287417B6 (sk) 2010-09-07
GT200000158A (es) 2002-03-16
MXPA02003156A (es) 2002-09-30
DE60041548D1 (de) 2009-03-26
CN1420879A (zh) 2003-05-28
CN1769282A (zh) 2006-05-10
EP1228063A2 (fr) 2002-08-07
AU782820B2 (en) 2005-09-01
WO2001023375A2 (fr) 2001-04-05
IL148880A0 (en) 2002-09-12
JP2003526632A (ja) 2003-09-09
CA2385817C (fr) 2010-05-04
HRP20020308B1 (fr) 2013-01-31
BG65860B1 (bg) 2010-03-31
CO5200835A1 (es) 2002-09-27
PL205957B1 (pl) 2010-06-30
AR082232A2 (es) 2012-11-21
HU230223B1 (en) 2015-10-28
HK1091818A1 (zh) 2007-01-26
EE05258B1 (et) 2010-02-15
BRPI0014382B8 (pt) 2021-05-25
RS50369B (sr) 2009-11-10
WO2001023375A3 (fr) 2002-05-02
YU22902A (sh) 2004-12-31
TW593315B (en) 2004-06-21
CZ20021444A3 (cs) 2002-08-14
HUP0202704A2 (hu) 2002-12-28
AU1569601A (en) 2001-04-30
CN100422172C (zh) 2008-10-01
KR20080091505A (ko) 2008-10-13
IL193367A0 (en) 2009-02-11
PL366342A1 (en) 2005-01-24
MY143377A (en) 2011-05-13
ATE422494T1 (de) 2009-02-15
CN100422173C (zh) 2008-10-01
ES2320525T3 (es) 2009-05-25
AR082231A2 (es) 2012-11-21
CA2385817A1 (fr) 2001-04-05
KR20080086547A (ko) 2008-09-25
EP1228063B1 (fr) 2009-02-11
HK1091819A1 (zh) 2007-01-26
BR0014382B1 (pt) 2014-04-01

Similar Documents

Publication Publication Date Title
MA25563A1 (fr) Pyridines et pyridazines substitues avec une activite inhibitrice angiogenese.
TR199902372A3 (tr) Sulfanilsilanlar.
PT1164870E (pt) Barra de cereais
MA25391A1 (fr) Inhibiteurs d'alcenyl et alcynyl metalloproteases.
ITBO990688A0 (it) Lavapiatti .
IT1312077B1 (it) Polipeptidi ad attivita' antiangiogenica.
NL1016477A1 (nl) Gemodificeerd oxymethyleenpolymeer.
ES1041748Y (es) Pantalon perfeccionado.
ES1039434Y (es) Estanteria.
ES1041981Y (es) Juego de combinacion.
ES1043980Y (es) Juego de sube y baja perfeccionado.
ES1042318Y (es) Alfombrilla perfeccionada.
ES1042757Y (es) Barbacoa perfeccionada.
ES1037917Y (es) Juego perfeccionado.
ES1039867Y (es) Parrilla asadora perfeccionada.
ES1042436Y (es) Posavasos perfeccionado.
ES1041012Y (es) Juego componible perfeccionado.
ES1039262Y (es) Juego perfeccionado.
ES1044268Y (es) Puzzle perfeccionado.
ES1043985Y (es) Tapon perfeccionado.
ES1044141Y (es) Juego didactico de ensamblaje de piezas tetraedricas regulares e irregulares.
ES1042789Y (es) Mueble perfeccionado.
ES1043798Y (es) Barbacoa perfeccionada.
ES1038530Y (es) Juego perfeccionado.
IT245730Y1 (it) Perfezionato catetere transettale.